The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Uusküla, Anneli ^a   Müürsepp, Andres ^b   Kawai, Kosuke ^c   Raag, Mait ^a   Jürisson, Mikk ^d   Pillsbury, Matthew ^e  

^a UNIVERSITY OF TARTU   (Estonia)

^b Merck Sharp and Dohme OÜ   (Estonia)

^c TEMPLE UNIVERSITY   (United States)

^d East Tallinn Central Hospital   (Estonia)

^e Atlas Data Systems   (United States)

Author keywords

Cervical cancer; Cost effectiveness; Estonia; Genital warts; HPV; Screening; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER MORTALITY; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; EPIDEMIOLOGY; ESTONIA; HEALTH ECONOMICS; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 4; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; ESTONIA; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRODUCIBILITY OF RESULTS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84879813092     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-304     Document Type: Article

References (27)

1. Seto K, Marra F, Raymakers A, Marra CA. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs 2012, 72(5):715-743. 10.2165/11599470-000000000-00000, 22413761.
2. Vanagas G, Padaiga Z, Kurtinaitis J, Logminiene Z. Cost-effectiveness of 12-and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania. Scand J Public Health 2010, 38(6):639-647. 10.1177/1403494810377684, 20639275.
3. Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ 2010, 13(1):110-118. 10.3111/13696990903546013, 20085477.
4. Obradovic M, Mrhar A, Kos M. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. Eur J Public Health 2010, 20(4):415-421. 10.1093/eurpub/ckp208, 20624834.
5. Kostinov MP, Zverev VV. [Economic effectiveness of vaccination against papilloma virus in the Russian Federation]. Zh Mikrobiol Epidemiol Immunobiol 2012, 2:43-50. [Article in Russian].
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010, Lyon, France: International Agency for Research on Cancer, http://globocan.iarc.fr.
7. Eesti haigekassa 2010 (HIF 2010) Haiguste ennetamise projektide 2010. aasta tulemused (The results of the disease prevention pojrects in 2010 2010, http://www.haigekassa.ee/uploads/userfiles/2010_HE_tulemused.pdf, Eesti haigekassa 2010 (HIF 2010).
8. Veerus P, Arbyn M, Amati C, Paolo B, EUROCHIP Working Group Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia. Tumori 2010, 96(4):524-528. EUROCHIP Working Group.
9. State agency of medicines, Estonia Marketing authorisation of medicinal products http://193.40.10.165/register/register.php?keel=eng&inim_vet=inim, State agency of medicines, Estonia.
10. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28:6858-6867. 10.1016/j.vaccine.2010.08.030, 20713101.
11. Estonian health insurance fund Data on insured by EHIF in 2008 2008, http://www.haigekassa.ee/uploads/userfiles/V15_4_kv__2008_kindlustatute_statistika_prioriteet_gruppides.xls, Estonian health insurance fund.
12. Statistics Estonia Population of Estonia http://www.stat.ee, Statistics Estonia.
13. National institutes of health Estonian Health Interview Survey 2006 (EHIS 2006) 2006, http://www2.tai.ee/ETeU/met_51.pdf, National institutes of health.
14. Surveillance, Epidemiology, and End Results (SEER) program Public-use data (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch 2005, http://www.seer.cancer.gov, Surveillance, Epidemiology, and End Results (SEER) program.
15. Liiv K, Lutsar K, Palm E, Uusküla A, Kiivet RA. Inimese papilloomiviiruse Vastaste vaktsiinide kulutõhusus Eestis 2011, Tartu Ülikooli tervishoiu instituut 2011. (Cost effectiveness of human papillomavirus vaccines in Estonia. Department of public health, University of Tartu, 2011), http://www.rahvatervis.ut.ee/bitstream/1/4921/1/Lutsar2011.pdf.
16. Estonian Health Board National immunization program implementation 2010, http://www.terviseamet.ee/nakkushaigused/vaktsineerimine/riiklik-immuniseerimiskava-ja-selle-taitmine.html, Estonian Health Board.
17. Gold MR, Siegel JE, Russell LB, Mce W. Cost-effectiveness in health and medicine: report of the panel on cost-effectiveness in health and medicine 1996, New York, NY: Oxford University Press.
18. Edejer TTT, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB. Making choices in health: WHO guide to cost-effectiveness analysis 2003, Geneva: World Health Organisation.
19. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22(12):2675-2686. 10.1093/annonc/mdr015, 21471563.
20. Eurostat GDP and main components - Current prices 2012, http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=nama_gdp_c&lang=en, Eurostat.
21. World health organization CHOosing Interventions that are Cost Effective (WHO-CHOICE) 2009, http://www.who.int/choice/book/en/index.html, World health organization.
22. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365(17):1576-1585. 10.1056/NEJMoa1010971, 22029979.
23. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2(10):868-878.
24. II Study Future Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 19:1915-1927. II Study Future Group.
25. International Agency for Research on Cancer IARC Handbooks of Cancer Prevention: Cervix Cancer Screening. 2005, 10. Lyon: IARC Press, International Agency for Research on Cancer.
26. van Ballegooijen M, van den Akker-van ME, Patnick J, Lynge E, Arbyn M, Anttila A. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000, 36(17):2177-2188. 10.1016/S0959-8049(00)00330-0, 11072201.
27. Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004, 91(5):935-941. 2409887, 15280916.